Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
- Disease/Condition
- Chronic Obstructive Pulmonary Disease (COPD)
- Drug/Device/Intervention
- Placebo
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- AstraZeneca
- Location
- Birmingham,Decatur,Sheffield,Peoria,Newport Beach,Denver,Boynton Beach,Ocala,Ormond Beach,Chicago,Bowling Green,Canton,Chesterfield,Hannibal,Las Vegas,Toms River,Bronx,Union,Elizabethton,El Paso,Houst, Argentina,Belgium,Brazil,Canada,China,France,Germany,Greece,Hungary,Ireland,Italy,Japan,Malaysia,Net
- Phase
- Phase 3
- Start date
- Sep 22, 2023
- End date
- Dec 07, 2026
- Enrollment
- 1240 participants
Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab
 administered subcutaneously (SC) in adult participants with symptomatic COPD with a history
 of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment.
 Participants should be receiving optimised treatment with inhaled maintenance therapy
 (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate)
 throughout at least the last 3 months prior to enrolment.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06040086
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06040086 through Pure Global AI's free database. This Phase 3 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 1240 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.